- AIM ImmunoTech Inc AIM has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD).
- The trial will evaluate the efficacy and safety of Ampligen in patients experiencing PCCD.
- Eighty subjects will be randomized 1:1 to receive twice-weekly infusions of Ampligen or placebo for 12 weeks.
- Related Content: AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study.
- Price Action: AIM stock is down 0.99% at $2.01 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
